During the past decade, UCLA Department of Medicine - Hematology & Oncology conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 12 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 6 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA Department of Medicine - Hematology & Oncology" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Celgene" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Seagen Inc." with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Department of Medicine - Hematology & Oncology" #1 collaborator was "ALX Oncology Inc." with 1 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Bionomics Limited" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator and "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Department of Medicine - Hematology & Oncology" are "Pancreatic Cancer" (3 trials), "Breast Cancer" (2 trials), "Malignant Melanoma" (2 trials), "Ovarian Cancer" (2 trials) and "Acral Lentiginous Melanoma" (1 trials). Many other conditions were trialed in "UCLA Department of Medicine - Hematology & Oncology" in a lesser frequency.

Most popular intervention types in "UCLA Department of Medicine - Hematology & Oncology" are "Drug" (24 trials), "Biological" (1 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (2 trials), "Gemcitabine" (2 trials), "Pembrolizumab" (2 trials), "Placebo" (2 trials) and "Prednisone" (2 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Department of Medicine - Hematology & Oncology" are 24 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "UCLA Department of Medicine - Hematology & Oncology". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in UCLA Department of Medicine - Hematology & Oncology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Department of Medicine - Hematology & Oncology, 9 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".